Studies on semicarbazide-sensitive amine oxidase in patients with diabetes mellitus and in transgenic mice

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1647, Issue 1-2, 2003, Pages 88-91

  Gokturk C ^a   Garpenstrand, H ^a   Nilsson, J ^b   Nordquist, J ^a   Oreland, L ^a   Forsberg Nilsson, K ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b BIOVITRUM AB   (Sweden)

Author keywords

HbA1c; Methylamine; Retinopathy; VAP 1

Indexed keywords

AMINE OXIDASE (COPPER CONTAINING); BIOLOGICAL MARKER; HEMOGLOBIN A1C; METHYLAMINE; SEMICARBAZIDE DERIVATIVE;

AORTA; CELLULAR DISTRIBUTION; CONFERENCE PAPER; DISEASE MARKER; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; ENZYME LOCALIZATION; ENZYME SUBSTRATE; ENZYMOLOGY; HISTOLOGY; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; RETINOPATHY; SMOOTH MUSCLE FIBER; TRANSGENIC MOUSE; URINALYSIS; URINE LEVEL; VASCULAR DISEASE; ANIMAL; BLOOD; DIABETIC RETINOPATHY; GENETICS; MOUSE; REVIEW;

ANIMALIA; MUS MUSCULUS;

AMINE OXIDASE (COPPER-CONTAINING); ANIMALS; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; HUMANS; MICE; MICE, TRANSGENIC; SEMICARBAZIDES;

EID: 17044455509     PISSN: 15709639     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1570-9639(03)00064-5     Document Type: Conference Paper

References (23)

1. Klein R., Klein B.E. Diabetic eye disease. Lancet. 350:1997;197-204.
2. Kohner E.M., Porta M., Hyer S.L. Pathogenesis of diabetic retinopathy and cataract. Pickup J., Williams G. Textbook of Diabetes. 1991;564-574 Blackwell, Oxford.
3. Reichard P., Nilsson B.Y., Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes. N. Engl. J. Med. 329:1993;304-309.
4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 352:1998;837-853.
5. Ekblom J. Potential therapeutic value of drugs inhibiting semicarbazide-sensitive amine oxidase: vascular cytoprotection in diabetes mellitus. Pharmacol. Res. 37:1998;87-92.
6. Bacala R., Cerami A. Advanced glycosylation: chemistry, biology and implications for diabetes and aging. Adv. Pharmacol. 23:1992;1-34.
7. Lewinsohn R. Mammalian monoamine-oxidizing enzymes, with special reference to benzylamine oxidase in human tissues. Braz. J. Med. Biol. Res. 17:1984;223-256.
8. Precious E., Gunn C.E., Lyles G.A. Deamination of methylamine by semicarbazide-sensitive amine oxidase in human umbilical artery and rat aorta. Biochem. Pharmacol. 37:1988;707-713.
9. Lyles G.A., Chalmers J. The metabolism of aminoacetone to methylglyoxal by semicarbazide-sensitive amine oxidase in human umbilical artery. Biochem. Pharmacol. 43:1992;1409-1414.
10. Thornalley P.J. Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification - a role in pathogenesis and antiproliferative chemotherapy. Gen. Pharmacol. 27:1996;565-573.
11. Moldes M., Feve B., Pairault J. Molecular cloning of a major mRNA species in murin 3T3 adipocyte lineage. Differentiation-dependent expression, regulation, and identification as semicarbazide-sensitive amine oxidase. J. Biol. Chem. 274:1999;9515-9523.
12. Enrique-Tarancon G., Marti L., Morin N., Lizcano J.M., Unzeta M., Sevilla L., Camps M., Palacin M., Testar X., Carpene C., Zorzano A. Role of semicarbazide-sensitive amine oxidase on glucose transport and GLUT4 recruitment to the cell surface in adipose cells. J. Biol. Chem. 273:1998;8025-8032.
13. El Hadri K., Moldes M., Mercier N., Andreani M., Pairault J., Feve B. Semicarbazide-sensitive amine oxidase in vascular smooth muscle cells. Differentiation-dependent expression and role in glucose uptake. Arterioscler. Thromb. Vasc. Biol. 22:2002;89-94.
14. Salmi M., Kalimo K., Jalkanen S. Induction and function of vascular adhesion protein-1 at sites of inflammation. J. Exp. Med. 178:1993;2255-2260.
15. Jalkanen S., Salmi M. Cell surface monoamine oxidises: enzymes in search of a function. EMBO J. 20:2001;3893-3901.
16. Nilsson S.E., Tryding N., Tufvesson G. Serum monoamine oxidase (MAO) in diabetes mellitus and some other internal diseases. Acta Med. Scand. 184:1968;105-108.
17. Elliott J., Fowden A.L., Callingham B.A., Sharman D.F., Silver M. Physiological and pathological influences on sheep blood plasma amine oxidase: effect of pregnancy and experimental alloxan-induced diabetes mellitus. Res. Vet. Sci. 50:1991;334-339.
18. Hayes B.E., Clarke D.E. Semicarbazide-sensitive amine oxidase activity in streptozotocin diabetic rats. Res. Commun. Chem. Pathol. Pharmacol. 69:1990;71-83.
19. Boomsma F., Derkx F.H.M., van den Meiracker A.H., Man in 't Veld A.J., Schalekamp M.A.D.H. Plasma semicarbazide-sensitive amine oxidase activity is elevated in diabetes mellitus and correlates with glycosylated haemoglobin. Clin. Sci. 88:1995;675-679.
20. Garpenstrand H., Ekblom J., Bäcklund L.B., Oreland L., Rosenqvist U. Elevated plasma semicarbazide-sensitive amine oxidase (SSAO) activity in Type 2 diabetes mellitus complicated by retinopathy. Diabet. Med. 16:1999;514-521.
21. Gronvall-Nordquist J.L., Backlund L.B., Garpenstrand H., Ekblom J., Landin B., Yu P.H., Oreland L., Rosenqvist U. Follow-up of plasma semicarbazide-sensitive amine oxidase activity and retinopathy in Type 2 diabetes mellitus. J. Diabetes Its Complicat. 15:2001;250-256.
22. Yu P., Zuo D.M. Oxidative deamination of methylamine by semicarbazide-sensitive amine oxidase leads to cytotoxic damage in endothelial cells. Possible consequences for diabetes. Diabetes. 42:1993;594-603.
23. Lyles G.A., Mc Dougall F.A. The enhanced daily excretion of urinary methylamine in rats treated with semicarbazide or hydralazine may be related to the inhibition of semicarbazide-sensitive amine oxidase activities. J. Pharm. Pharmacol. 41:1989;97-100.